Clinical Trial

Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea

Study acronym: ASTRAL
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 8, 2025 (before its estimated June 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study if to evaluate the efficacy and safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-11-29; most recent amendment 2025-12-01.
Status change: Not Yet Recruiting → Recruiting 2025-12-01
Trial Details
NCT Number NCT05640232
Lead Sponsor EMS
Conditions Primary Dysmenorrhea
Enrollment 238 participants
Start Date 2025-06-11
Primary Completion 2026-06-28 (estimated)
Study Completion 2027-01-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-08